Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018222689) ANTIBODIES AND MOLECULES THAT IMMUNOSPECIFICALLY BIND TO BTN1A1 AND THE THERAPEUTIC USES THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/222689 International Application No.: PCT/US2018/035090
Publication Date: 06.12.2018 International Filing Date: 30.05.2018
IPC:
C07K 16/28 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
Applicants:
STCUBE & CO., INC. [KR/KR]; 7 Floor (Samsung-dong, Jungsoek Building) Samsung-ro 96 Gil 12 Gangnam-gu, Seoul, 06164, KR
Inventors:
YOO, Stephen, Sunghan; US
CHUNG, Ezra, Myung, Chul; US
BONG, Yong-Sik; US
KIM, Yong-Soo; US
PARK, Andrew, H.; US
Agent:
SPAIN, Astrid, R.; US
INSOGNA, Anthony, M.; US
ANTLER, Adriane, M.; US
GEORGE, Nikolaos, C.; US
ROWAN, Thomas, G.; US
Priority Data:
62/513,38931.05.2017US
Title (EN) ANTIBODIES AND MOLECULES THAT IMMUNOSPECIFICALLY BIND TO BTN1A1 AND THE THERAPEUTIC USES THEREOF
(FR) ANTICORPS ET MOLÉCULES SE LIANT DE MANIÈRE IMMUNOSPÉCIFIQUE À BTN1A1 ET LEURS UTILISATIONS THÉRAPEUTIQUES
Abstract:
(EN) Provided herein are molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to BTN1A1 dimers, such as anti-BTN1A1 dimer antibodies. Methods of making and using these molecules are also provided, including methods of using them in cancer therapies, or as cancer diagnostics.
(FR) La présente invention concerne des molécules possédant un fragment de liaison à l'antigène se liant de manière immunospécifique à BTN1A1, tels que des anticorps anti-BTN1A1. Les molécules de l'invention comprennent celles possédant un fragment de liaison à l'antigène se liant de manière immunospécifique aux dimères de BTN1A1, tels que des anticorps de dimère anti-BTN1A1. La présente invention concerne également des procédés de fabrication et d'utilisation de ces molécules, ainsi que des procédés d'utilisation de celles-ci dans des thérapies anticancéreuses ou comme agents de diagnostic d'un cancer.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)